Gierse Martin, Nagel Luca, Keim Michael, Lucas Sebastian, Speidel Tobias, Lobmeyer Tobias, Winter Gordon, Josten Felix, Karaali Senay, Fellermann Maximilian, Scheuer Jochen, Müller Christoph, van Heijster Frits, Skinner Jason, Löffler Jessica, Parker Anna, Handwerker Jonas, Marshall Alastair, Salhov Alon, El-Kassem Bilal, Vassiliou Christophoros, Blanchard John W, Picazo-Frutos Román, Eills James, Barth Holger, Jelezko Fedor, Rasche Volker, Schilling Franz, Schwartz Ilai, Knecht Stephan
NVision Imaging Technologies GmbH, 89081 Ulm, Germany.
Institute for Quantum Optics (IQO) and Center for Integrated Quantum Science and Technology (IQST), Ulm University, 89081 Ulm, Germany.
J Am Chem Soc. 2023 Mar 15;145(10):5960-5969. doi: 10.1021/jacs.2c13830. Epub 2023 Mar 1.
We present a versatile method for the preparation of hyperpolarized [1-C]fumarate as a contrast agent for preclinical MRI, using parahydrogen-induced polarization (PHIP). To benchmark this process, we compared a prototype PHIP polarizer to a state-of-the-art dissolution dynamic nuclear polarization (d-DNP) system. We found comparable polarization, volume, and concentration levels of the prepared solutions, while the preparation effort is significantly lower for the PHIP process, which can provide a preclinical dose every 10 min, opposed to around 90 min for d-DNP systems. With our approach, a 100 mM [1-C]-fumarate solution of volumes up to 3 mL with 13-20% C-hyperpolarization after purification can be produced. The purified solution has a physiological pH, while the catalyst, the reaction side products, and the precursor material concentrations are reduced to nontoxic levels, as confirmed in a panel of cytotoxicity studies. The usage of the hyperpolarized fumarate as a perfusion agent in healthy mice and the metabolic conversion of fumarate to malate in tumor-bearing mice developing regions with necrotic cell death is demonstrated. Furthermore, we present a one-step synthesis to produce the C-labeled precursor for the hydrogenation reaction with high yield, starting from CO as a cost-effective source for C-labeled compounds.
我们展示了一种通用方法,用于制备超极化的[1-C]富马酸盐作为临床前MRI的造影剂,该方法采用仲氢诱导极化(PHIP)。为了评估这一过程,我们将一个原型PHIP极化器与一个最先进的溶解动态核极化(d-DNP)系统进行了比较。我们发现所制备溶液的极化、体积和浓度水平相当,而PHIP过程的制备工作量显著更低,该过程每10分钟就能提供一个临床前剂量,而d-DNP系统则需要约90分钟。采用我们的方法,纯化后可制备出体积达3 mL、C-超极化率为13-20%的100 mM [1-C] - 富马酸盐溶液。纯化后的溶液具有生理pH值,同时催化剂、反应副产物和前体物质的浓度降低到无毒水平,这在一系列细胞毒性研究中得到了证实。本文展示了超极化富马酸盐在健康小鼠中作为灌注剂的应用,以及在患有坏死性细胞死亡的荷瘤小鼠中富马酸盐向苹果酸的代谢转化。此外,我们还展示了一种一步合成法,以高收率制备用于氢化反应的C标记前体,该方法以CO作为C标记化合物的经济有效来源。